New cancer drug enters first human trials
NCT ID NCT06188208
Summary
This is the first study in people to test a new experimental drug called VVD-130850, which blocks a protein called STAT3 that helps cancer grow. The main goal is to find a safe dose and see how the body handles the drug, both alone and combined with an existing immunotherapy. It will enroll about 125 adults with advanced solid tumors or blood cancers that have not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blacktown Hospital
Blacktown, New South Wales, Australia
-
California Research Institute
Los Angeles, California, 90027, United States
-
Cancer Research South Australia
Adelaide, Australia
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Gold Coast University Hospital
Southport, Queensland, Australia
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
ICON Cancer Research
South Brisbane, Australia
-
MDACC
Houston, Texas, 77030, United States
-
NEXT Austin
Austin, Texas, 78758, United States
-
NEXT Dallas
Irving, Texas, 75039, United States
-
NEXT Madrid
Madrid, Spain
-
NEXT San Antonio
San Antonio, Texas, 78299, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Orange Health Service
Orange, New South Wales, Australia
-
START Barcelona Hospital HM Nou Delfos
Barcelona, Spain
-
START Madrid CIOCC
Madrid, Spain
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Start Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Vall d'Hebron
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.